The estimated Net Worth of Sciences Opportunities Fund... is at least $1.21 Milion dollars as of 19 August 2020. Sciences Fund owns over 869,283 units of Teligent Inc stock worth over $2,978 and over the last 4 years Sciences sold TLGT stock worth over $1,208,303.
Sign up
Sciences Fund TLGT stock SEC Form 4 insiders trading
Sciences has made over 1 trades of the Teligent Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Sciences sold 869,283 units of TLGT stock worth $1,208,303 on 19 August 2020.
The largest trade Sciences's ever made was selling 869,283 units of Teligent Inc stock on 19 August 2020 worth over $1,208,303. On average, Sciences trades about 869,283 units every 0 days since 2020. As of 19 August 2020 Sciences still owns at least 17,515 units of Teligent Inc stock.
You can see the complete history of Sciences Fund stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Teligent Inc
Over the last 9 years, insiders at Teligent Inc have traded over $1,419,503 worth of Teligent Inc stock and bought 245,910 units worth $400,963 . The most active insiders traders include James C Gale, Sciences Opportunities Fund... a John E Celentano. On average, Teligent Inc executives and independent directors trade stock every 89 days with the average trade being worth of $8,816. The most recent stock trade was executed by Philip K Yachmetz on 16 July 2021, trading 7,835 units of TLGT stock currently worth $1,332.
What does Teligent Inc do?
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.
What does Teligent Inc's logo look like?
Complete history of Sciences Fund stock trades at Teligent Inc
Teligent Inc executives and stock owners
Teligent Inc executives and other stock owners filed with the SEC include:
-
John Celentano,
Chairman of the Board -
Steven Koehler,
Independent Director -
Bhaskar Chaudhuri,
Independent Director -
Carole Ben-Maimon,
Independent Director -
Thomas Sabatino,
Independent Director -
Philip Yachmetz,
Chief Legal Officer, Corporate Secretary -
Timothy Sawyer,
President, Chief Executive Officer, Director -
Martin Wilson,
General Counsel -
Stephen Richardson,
Chief Scientific Officer -
Jenniffer Collins,
CFO -
Narendra N Borkar,
Director -
Sciences Opportunities Fund...,
-
James C Gale,
Director -
Jason Grenfell Gardner,
President & CEO -
Damian Finio,
CFO -
Paolantonio Ernest Robert De,
Chief Financial Officer -
William S Marth,
Director -
R Carter Pate,
Director